Gainesville, FL, United States of America

Nicholas Muzyczka

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: University of Florida Research Foundation Inc., The State University of New York, The UAB Research Foundation (The University of Alabama at Birmingham). Active years: 1992-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicholas Muzyczka. Retrieved from https://idiyas.com/inventor/nicholas-muzyczka

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 88.2

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 3.5

ph-index = 10

Forward Citations = 1,396(Granted Patents)

Location History:

Stony Brook, NY (US) (1992)
Gainesville, FL (US) (1997 - 2022)

Company Filing History:

11 out of 3,052

University of Florida Research Foundation Inc.

patents

4 out of 2,046

The State University of New York

patents

1 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

4. 1 out of 1,327

The University of North Carolina at Chapel Hill

patents

5. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2022

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11332502 - Modified AAV capsid proteins and uses thereof (2022-05-17),

2. 11000597 - Engineered receptor/ligand system for delivery of therapeutic agents (2021-05-11),

3. 8802080 - Raav expression systems for genetic modification of specific capsid proteins (2014-08-12),

4. 8278428 - Mitochondrial nucleic acid delivery systems (2012-10-02),

5. 7098374 - Human disease modeling using somatic gene transfer (2006-08-29),

6. 7094604 - Production of pseudotyped recombinant AAV virions (2006-08-22),

7. 6660514 - Method of preparing recombinant adeno-associated virus compositions (2003-12-09),

8. 6627617 - Temperature-sensitive regulation of viral vector production (2003-09-30),

9. 6146874 - Method of preparing recombinant adeno-associated virus compositions (2000-11-14),

10. 6020192 - Humanized green fluorescent protein genes and methods (2000-02-01),

11. 5968750 - Humanized green fluorescent protein genes and methods (1999-10-19),

12. 5874304 - Humanized green fluorescent protein genes and methods (1999-02-23),

13. 5741683 - In vitro packaging of adeno-associated virus DNA (1998-04-21),

14. 5688676 - In vitro packaging of adeno-associated virus DNA (1997-11-18),

15. 5688675 - In vitro packaging of adeno-associated virus DNA (1997-11-18),

Title: Innovations and Contributions of Inventor Nicholas Muzyczka

Introduction

Nicholas Muzyczka is a prominent inventor based in Gainesville, FL (US), known for his significant contributions to the field of gene therapy. With a total of 17 patents, he has made remarkable advancements in the use of adeno-associated viral (AAV) particles for gene delivery.

Latest Patents

Among his latest patents are the "Modified AAV capsid proteins and uses thereof," which focus on enhancing the ability of AAV particles to transduce retinal cells. This innovation is crucial for gene delivery to the retina, a vital area in treating various ocular diseases. Another notable patent is the "Engineered receptor/ligand system for delivery of therapeutic agents," which addresses the challenges of delivering therapeutic and diagnostic agents across the blood-brain barrier and blood-cerebrospinal fluid barrier. This system utilizes an engineered dockerin-cohesin approach to improve targeted delivery.

Career Highlights

Throughout his career, Muzyczka has been associated with esteemed institutions such as the University of Florida Research Foundation and the State University of New York. His work has significantly impacted the field of gene therapy, particularly in developing innovative delivery systems for therapeutic agents.

Collaborations

Muzyczka has collaborated with notable colleagues, including Sergei Zolotukhin and William W. Hauswirth, further enhancing the scope and impact of his research.

Conclusion

Nicholas Muzyczka's contributions to gene therapy and innovative delivery systems have established him as a leading inventor in his field. His work continues to pave the way for advancements in medical treatments and therapies.

Profile summary based on public USPTO records.